42 results about "Arteriosclerosis obliterans" patented technology

An agent for improving abnormal glucose tolerance or a preventive and / or a remedy for diseases caused by abnormal glucose tolerance containing a chymase inhibitor as the active ingredient. Examples of the diseases caused by abnormal glucose tolerance include diabetes and / or complications of diabetes. Examples of the complications of diabetes include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinemia, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, vasculitis, brain infarction, hypertension, renal insufficiency, neuropathy, nephritis, renal aneurysm, renal infarction, obesity and so on.

It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and / or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

A novel polypeptide, and an antibacterial agent, antifungal agent and / or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and / or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).

The invention discloses a compound cell preparation, a preparation method and application of the preparation. The preparation comprises autologous platelet rich plasma (PRP), autologous adipose derived stromal cells (ADSCs) and endothelial progenitor cells (EPCs) of ADSC sources. The preparation method comprises the following steps that fat is collected, and adipocyte is separated; the adipocyte is cultured through an ADSC culture medium to obtain P2-generation autologous ADSCs; the P2-generation autologous ADSCs are cultured through an EPC culture medium to obtain EPCs of P0-generation ADSC sources; anticoagulation peripheral blood of a receptor is collected and centrifuged to obtain PRP, and the application of the compound cell preparation in the medicine for treating lower extremity arteriosclerosis obliterans due to diabetes is achieved. The compound cell preparation has the advantages that the EPC culture medium is adopted for inducing the ADSCs to be cultured, the EPCs with the expression percentage of CD133 as 68.72+ / -11.60% and the expression percentage of vWF as 75.91+ / -9.83% are obtained, bone marrow or mobilized peripheral blood does not need to be collected, and after affected parts of patients with lower extremity arteriosclerosis obliterans due to diabetes are injected with the preparation, the limb pain feeling and cold feeling can be lowered, and the new generation rate of collateral vessels is 100%; the total survival rate is 78.12%, the limb salvage survival rate is 68.00%, and the survival life of artificial limbs of the patients can be effectively prolonged.

The objective of the invention is to provide an agent for prevention and treatment of acute renal failure which is caused by the following lasting or aggravated diseases: systemic inflammatory response syndrome caused by trauma, burn, pancreatitis, septicemia or infection; DIC syndrome; multiple organ failure; peripheral arterial occlusive disease; occlusive atherosclerosis; and crush syndrome; or post-transplantation complication. The invention is an agent for prevention and treatment of acute renal failure, which contains a hydantoin derivative represented by the general formula below as an active ingredient. Among such compounds, (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide is particularly preferable. (Formula) (In the formula, X represents a halogen atom or a hydrogen atom, and R<1> and R<2> independently represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or R<1> and R<2> are combined with nitrogen atom to which R<1> and R<2> are connected or optionally another nitrogen atom or oxygen atom to form 5- and 6-membered heterocycle.

The invention is concerned with use of oral inorganic pyrophosphate for preventing and / or reducing tissue calcification, particularly soft tissue calcification, and / or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type II, cardiovascular disorder, or atherosclerosis.

The invention relates to the technical field of traditional Chinese medicines, and discloses a Yiwangao ointment and a preparation method thereof. The Yiwangao ointment disclosed by the invention is prepared by decocting radix astragali, Chinese angelica, ground beetle, radix aconiti, radix aconiti kusnezoffii, cochinchina momordica seed, centipede, frankincense, myrrh, dragon's blood, yellow wax, minium and sesame oil. In the invention, multiple pure natural raw materials are selected as the components of the compound traditional Chinese medicine Yiwangao ointment; the Yiwangao ointment is prepared by decocting with a unique process, realizes a remarkably curative effect on curing symptoms such as angiitis, arteriosclerosis obliterans, diabetic foot, deep and shallow venous thrombus, venous ulcer, various bone diseases, lumbar disc herniation, gout, synovitis, stubborn dermatitis, malignant sore, burn, frostbite and the like, and has the advantages of convenience in use, low cost, remarkable curative effect and the like.